AstraZeneca: phase 3 study of cancer drug misses targets
(CercleFinance.com) - AstraZeneca said on Friday that its phase 3 trial of a drug combination intended to treat metastatic bladder cancer has failed to meet its targets.
The Anglo-Swedish company said the late-stage trial for Imfinzi and Imfinzi plus tremelimumab in stage IV bladder cancer did not meet the primary endpoints of improving overall survival versus standard-of-care chemotherapy.
The trial included patients whose tumour cells and/or tumour-infiltrating immune cells express high levels of PD-L1, or regardless of their PD-L1 expression for Imfinzi plus tremelimumab.
Note that Imfinzi is also being tested in earlier stages of bladder cancer.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Anglo-Swedish company said the late-stage trial for Imfinzi and Imfinzi plus tremelimumab in stage IV bladder cancer did not meet the primary endpoints of improving overall survival versus standard-of-care chemotherapy.
The trial included patients whose tumour cells and/or tumour-infiltrating immune cells express high levels of PD-L1, or regardless of their PD-L1 expression for Imfinzi plus tremelimumab.
Note that Imfinzi is also being tested in earlier stages of bladder cancer.
Copyright (c) 2020 CercleFinance.com. All rights reserved.